Orbia Fluor & Energy Materials’ pharmaceutical business unit has published a new whitepaper about the industry’s ongoing transition to pressurised metered dose inhalers (pMDIs) to low global warming ...

The Airsupra inhaler reduces severe asthma attacks by 47%, combining immediate relief with anti-inflammatory action.

AstraZeneca is conducting a Phase III study titled ‘A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol ...

India: Inhalation therapy remains a cornerstone in the treatment of obstructive, inflammatory, and infectious respiratory ...

Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million ...

The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%.

Professor Omar Usmani and Respiratory Effectiveness Group colleagues outline a pragmatic approach to inhaler choice and ...

The global airway disease treatment market is poised for significant expansion, with a projected increase from USD 2.3 ...

The Business Research Company The Business Research Company's Aerosol Drug Delivery Devices Global Market Report 2025 – Market Size, Trends ...

Urgent recall for asthma medication taken by thousands as health chiefs warn of wrong dose instruction Find out which batches of the medication have been recalled below ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

European regulators have given their backing to a new eco-friendly inhaler that could help curb health care’s climate impact. Drugmaker AstraZeneca said the new inhaler has a fraction of the ...